{"id":"saxagliptin-metformin-xr","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Gastrointestinal disturbance (nausea, diarrhea, abdominal pain)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Lactic acidosis (rare, metformin-associated)"}]},"_chembl":{"chemblId":"CHEMBL494397","moleculeType":"Small molecule","molecularWeight":"165.63"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that prolongs the action of incretin hormones (GLP-1 and GIP), which stimulate insulin secretion in response to meals. Metformin XR is a biguanide that decreases hepatic gluconeogenesis and improves peripheral insulin sensitivity. Together, they provide complementary glucose-lowering effects through different mechanisms.","oneSentence":"Saxagliptin inhibits DPP-4 to increase incretin levels and lower blood glucose, while metformin XR reduces hepatic glucose production and improves insulin sensitivity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:33:34.947Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT01267448","phase":"PHASE4","title":"Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia","status":"COMPLETED","sponsor":"Cook County Health","startDate":"2014-09-09","conditions":"Diabetes Mellitus Type 2, Hyperglycemia","enrollment":100},{"nctId":"NCT03138356","phase":"PHASE1","title":"Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-05-25","conditions":"Type 2 Diabetes Mellitus","enrollment":126},{"nctId":"NCT03169959","phase":"PHASE1","title":"A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-05-29","conditions":"Type 2 Diabetes Mellitus","enrollment":85},{"nctId":"NCT01754142","phase":"","title":"Korean Post-marketing Surveillance for Kombiglyze XR®","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-11-24","conditions":"Diabetes Mellitus, Type 2","enrollment":755},{"nctId":"NCT02022007","phase":"PHASE3","title":"Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis","status":"COMPLETED","sponsor":"Woman's","startDate":"2014-03","conditions":"Polycystic Ovary Syndrome, Disorder of Glucose Regulation","enrollment":38},{"nctId":"NCT01606007","phase":"PHASE3","title":"Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-07","conditions":"Type 2 Diabetes","enrollment":1282},{"nctId":"NCT01434186","phase":"PHASE3","title":"A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-05","conditions":"Diabetes Mellitus, Type 2","enrollment":32},{"nctId":"NCT01525225","phase":"PHASE1","title":"Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2012-09","conditions":"Type 2 Diabetes Mellitus","enrollment":4},{"nctId":"NCT00683657","phase":"PHASE3","title":"Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-07","conditions":"Type 2 Diabetes","enrollment":93},{"nctId":"NCT01192139","phase":"PHASE1","title":"Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin XR Tablet (Manufactured in Mt Vernon, IN) Relative to 5 mg Saxagliptin Tablet and 500 mg Metformin XR Tablet (Manufactured in Evansville, IN)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-11","conditions":"Diabetes Mellitus","enrollment":30},{"nctId":"NCT00918138","phase":"PHASE3","title":"Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-08","conditions":"Type 2 Diabetes","enrollment":219},{"nctId":"NCT01192152","phase":"PHASE1","title":"Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR (Manufactured in Mt Vernon, IN) Relative to 5 mg of Onglyza and 2 × 500 mg Glucophage XR","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-11","conditions":"Diabetes Mellitus","enrollment":30},{"nctId":"NCT01365091","phase":"PHASE1","title":"Bioequivalence Study of Fixed-dose Combinations and Coadministered Individual Tablets of Saxagliptin/Metformin-Brazil","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-06","conditions":"Type 2 Diabetes Mellitus","enrollment":112},{"nctId":"NCT01874080","phase":"PHASE1","title":"Bioequivalence Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-06","conditions":"Diabetes","enrollment":56},{"nctId":"NCT01305551","phase":"PHASE1","title":"BE Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin HCl XR Tablet Relative to a 5 mg Saxagliptin (Onglyza™) Tablet and a 500 mg Metformin HCl XR (Glifage® XR Marketed in Brazil by Merck S.A.) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States","status":"WITHDRAWN","sponsor":"AstraZeneca","startDate":"2011-03","conditions":"Type 2 Diabetes","enrollment":""},{"nctId":"NCT01755494","phase":"PHASE1","title":"A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-02","conditions":"Type 2 Diabetes Mellitus(T2DM)","enrollment":64},{"nctId":"NCT01441869","phase":"PHASE1","title":"Study in Healthy Subjects to Measure Amount of Drug in Blood After Dosing With Different Saxagliptin / Metformin Produc","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-10","conditions":"Bioequivalence, Log-transformed AUCss and Cmax,ss Values for Saxagliptin and Metformin","enrollment":28},{"nctId":"NCT00960076","phase":"PHASE3","title":"An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-08","conditions":"Type 2 Diabetes","enrollment":282}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Kombiglyze XR","Combination DPP-4 inhibitor and Glucophage XR"],"phase":"phase_3","status":"active","brandName":"Saxagliptin-Metformin XR","genericName":"Saxagliptin-Metformin XR","companyName":"Woman's","companyId":"woman-s","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Saxagliptin inhibits DPP-4 to increase incretin levels and lower blood glucose, while metformin XR reduces hepatic glucose production and improves insulin sensitivity. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}